Key takeaways
- The MHRA said on 15 October 2026: “Retatrutide has not been authorised for use in the UK.” In July 2026 it said that “anyone selling this product is doing so illegally”.
- Under the Human Medicines Regulations 2012, selling or supplying an unauthorised medicinal product is an offence, with a maximum of two years’ imprisonment, a fine or both on indictment.
- The MHRA’s Criminal Enforcement Unit has named retatrutide in releases on four operations since October 2025, in Northampton, Sleaford and Grantham, near Northampton again, and Birmingham.
- A full-text search of UK legislation found no mention of retatrutide, the Misuse of Drugs Act 1971 does not list it, and the emc lists no product containing it (18 Nov 2026).
- Sport runs on its own rulebook: WADA’s 2026 and 2027 Prohibited Lists do not name retatrutide, WADA says a peptide not named on the List “may still be prohibited”, and anti-doping organisations decide how class S0 applies.
01What has the MHRA said about retatrutide?
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines in the UK. It has named retatrutide in five press releases since October 2025 (GOV.UK search, 18 Nov 2026). Three of them set out its position in its own words.
| Date | MHRA release | What it said about retatrutide |
|---|---|---|
| 24 Oct 2025 | Northampton facility, notes to editors | “Retatrutide is GLP-1 medicine in clinical development, which has not been approved for UK use. Outside of authorised clinical trials, any products being sold in the UK that claim to contain retatrutide are likely to be illegal and are potentially dangerous to people’s health.” |
| 24 Jul 2026 | “No summer shortcut for safe weight loss” | It “has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally.” The products “haven’t been tested for safety, quality or effectiveness and there’s no guarantee that they even contain retatrutide.” |
| 15 Oct 2026 | Birmingham seizure | “Retatrutide has not been authorised for use in the UK. Products being sold as retatrutide outside legitimate clinical trials are being supplied illegally and could pose serious risks to public health.” |
The wording changed over the year. In October 2025 the MHRA wrote that such products were “likely to be illegal”. From July 2026 it said that selling them is illegal.
The MHRA acts on this through general medicines law. In May 2026 two men were arrested “on suspicion of offences under the Human Medicines Regulations 2012” after a raid on a site the MHRA believed was used to make unlicensed weight-loss medicines, “including retatrutide and tirzepatide”.
02What does UK medicines law say?
UK law keeps no list of peptides, and we found no UK legislation that names retatrutide (legislation.gov.uk, 18 Nov 2026). Medicines law asks what a product is, and then who may sell, supply or advertise it.
Is it a medicine? Regulation 2 of the Human Medicines Regulations 2012 has two limbs. A medicinal product is a substance “presented as having properties of preventing or treating disease in human beings”, or one that may be used by or given to people with a view to “restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action”.
Selling and supplying. Regulation 46(1): “A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product.” A product is unauthorised when none of a UK marketing authorisation, a certificate of registration, a traditional herbal registration or an Article 126a authorisation is in force for it. Regulation 47 makes a breach an offence. On indictment the maximum is “a fine, to imprisonment not exceeding two years or to both”.
Advertising. Regulation 279 says a person “may not publish an advertisement in Great Britain for a medicinal product” unless a UK marketing authorisation, a temporary authorisation, a certificate of registration or a traditional herbal registration is in force for it. Regulation 303 makes a breach an offence, with the same two-year maximum on indictment.
| Provision | What it covers | Maximum on indictment |
|---|---|---|
| Human Medicines Regulations 2012, reg 2 | Defines a medicinal product, by presentation or by function | Definition only |
| Reg 46(1) | Selling or supplying, or offering to, an unauthorised medicinal product | 2 years, a fine or both (reg 47) |
| Reg 279 | Advertising a medicinal product in Great Britain with no authorisation in force | 2 years, a fine or both (reg 303) |
| Misuse of Drugs Act 1971, Sch 2 | Controlled drugs, Classes A to C | Retatrutide is not listed |
The rules that apply to every peptide are on are peptides legal in the UK? What a label can and cannot change is on what “research use only” means.
03What have UK authorities done, and when?
A dated record, taken from the MHRA’s own releases. Each one names retatrutide.
| Date | Who | What happened |
|---|---|---|
| 24 Oct 2025 | MHRA Criminal Enforcement Unit | Announces it has dismantled an illicit manufacturing facility at a Northampton warehouse, seizing unlicensed retatrutide and tirzepatide pens awaiting dispatch, empty pens and raw chemical ingredients |
| 25 Feb 2026 | MHRA Criminal Enforcement Unit | Announces raids on a farm near Sleaford and a residential address in Grantham, believed to be used to make and distribute “unlicensed weight loss medicines, including retatrutide and tirzepatide, as well as peptide products”; almost 2,000 doses seized |
| 28 May 2026 | MHRA Criminal Enforcement Unit | Raids a country estate near Northampton believed to be used for the same kinds of product; around 12,000 doses recovered; two men arrested on suspicion of offences under the Human Medicines Regulations 2012 (announced 29 May) |
| 24 Jul 2026 | MHRA | Says retatrutide “has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally” |
| 14 Oct 2026 | MHRA and West Midlands Police | Seize over 12,000 fake retatrutide and tirzepatide pens, and packaging for around 30,000 more products, at an industrial unit in Birmingham (announced 15 Oct) |
| 18 Nov 2026 | Our check | A legislation.gov.uk full-text search finds no mention of retatrutide; the emc lists no product containing it |
The releases report raids, seizures and arrests. They do not report charges or court outcomes.
04Does any UK law or licence name retatrutide?
Controlled drugs. No. Retatrutide is not listed in Schedule 2 to the Misuse of Drugs Act 1971, which sets out Classes A, B and C. We read the whole schedule, as revised on legislation.gov.uk, on 18 November 2026. The peptide hormones that schedule does control, such as somatropin, sit in Class C. Not being a controlled drug does not settle the medicines question above: the two regimes are separate.
Legislation. A full-text search of legislation.gov.uk for “retatrutide” returned no results on 18 November 2026. The same search for “somatropin” returned 30.
Licensed medicines. The emc, the UK database of product information for licensed medicines, returned “No search results for retatrutide” on 18 November 2026. The same search for tirzepatide, an approved prescription medicine, returned 6 results. We could not run the MHRA Products search, which needs a browser.
Anywhere else. Retatrutide is investigational and not approved anywhere. The TGA, Australia’s regulator, wrote on 5 November 2026 that it “has not been approved by the TGA or any comparable international regulator”. The research on it is in our retatrutide research guide.
05How is retatrutide treated in UK sport?
Sport that follows the World Anti-Doping Code runs on WADA’s Prohibited List, not on medicines law. Neither the 2026 List nor the 2027 List, in force from 1 January 2027, names retatrutide.
That is not the whole answer. Class S0 prohibits at all times any pharmacological substance not addressed elsewhere on the List and “with no current approval by any governmental regulatory health authority for human therapeutic use”. WADA’s notes on the 2027 List add that a peptide not specifically named “may still be prohibited”. WADA and anti-doping organisations decide how S0 applies, and we draw no conclusion for retatrutide here. The List text, and what anti-doping bodies have said, are on is retatrutide banned in sport?
06What changed in 2026?
The law did not change. The MHRA’s statements and its enforcement did.
No new UK law. We found no UK instrument that names retatrutide (legislation.gov.uk search, 18 Nov 2026).
Firmer wording. From “likely to be illegal” in October 2025 to “anyone selling this product is doing so illegally” in July 2026.
More enforcement. Three operations in 2026 whose releases name retatrutide, one of them with arrests.
Outside the UK. FDA warning letters dated 24 August 2026 listed products sold online as retatrutide among unapproved new drugs, and in November 2026 the TGA reported that tested products from one brand, sold as retatrutide, held less of it than their labels stated. More: is retatrutide legal in the US? and is retatrutide legal in Australia?
07What we don’t know
What happened after the raids. The releases report seizures and arrests. They do not report charges or verdicts.
MHRA Products. We could not run its search. Our check for a licensed UK product is the emc result above.
Northern Ireland. Parts of these rules differ there: regulation 279, for example, has separate Northern Ireland provisions. We have not covered them.
Future authorisation. Whether retatrutide will be authorised in the UK, and when. The MHRA’s statements describe it as not authorised.
Changes are logged in our regulatory changelog.
This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.